Lumexa Imaging (LMRI) announced the appointment of Kyle Lynch as its new Chief Growth Officer, CGO. Lynch joins the executive leadership team to lead the company’s enterprise growth strategy, with responsibility for expanding Lumexa Imaging’s platform through joint ventures, acquisitions, and de novo development. Prior to joining Lumexa Imaging, Lynch served as SVP of Strategy and Development at SCA Health
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LMRI:
- Lumexa Imaging price target lowered to $15 from $23 at Barclays
- Lumexa Imaging Reaffirms Full-Year 2026 Financial Guidance
- Lumexa Imaging Earnings Call Highlights Growth Momentum
- Maintaining Buy on LMRI: Market Overdiscounts Consolidated Centers, Creating Upside to $17 Target
- Lumexa Imaging price target lowered to $17 from $23 at Raymond James